{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&q=KRAS", "query": { "q": "KRAS", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&q=KRAS&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T16:00:05.711Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00403767", "title": "An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Stroke", "Embolism" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Matching placebo for Rivaroxaban arm (Warfarin placebo)", "type": "DRUG" }, { "name": "Matching placebo for Warfarin arm (Rivaroxaban placebo)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14269, "start_date": "2006-12", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2014-04-29", "last_synced_at": "2026-07-24T16:00:05.711Z", "location_count": 295, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Geneva", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Pell City", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00403767" }, { "nct_id": "NCT07650357", "title": "A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Non Small Cell Lung Cancer", "Pancreatic Carcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "CLSP-5282", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clasp Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2026-07", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-07-24T16:00:05.711Z", "location_count": 4, "location_summary": "Durham, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07650357" }, { "nct_id": "NCT03996369", "title": "Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Etrasimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arena Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 354, "start_date": "2020-09-15", "completion_date": "2021-12-07", "has_results": true, "last_update_posted_date": "2022-12-21", "last_synced_at": "2026-07-24T16:00:05.711Z", "location_count": 62, "location_summary": "Dothan, Alabama • Mobile, Alabama • Sun City, Arizona + 54 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03996369" }, { "nct_id": "NCT04586231", "title": "A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Belzutifan", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 747, "start_date": "2021-02-25", "completion_date": "2027-02-11", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-07-24T16:00:05.711Z", "location_count": 33, "location_summary": "Chandler, Arizona • Los Angeles, California • Orange, California + 27 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04586231" }, { "nct_id": "NCT00030966", "title": "Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Natalizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 1200, "start_date": "2002-01", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2009-06-18", "last_synced_at": "2026-07-24T16:00:05.711Z", "location_count": 72, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030966" }, { "nct_id": "NCT06863129", "title": "Proximal FEmur Reconstruction or Internal Fixation fOR Metastases (PERFORM) Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Metastatic Bone Disease" ], "interventions": [ { "name": "Internal Fixation", "type": "PROCEDURE" }, { "name": "Resection and reconstruction", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Michelle Ghert, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 334, "start_date": "2025-02-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-07-08", "last_synced_at": "2026-07-24T16:00:05.711Z", "location_count": 7, "location_summary": "Aurora, Colorado • Fort Wayne, Indiana • Baltimore, Maryland + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Albany", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06863129" }, { "nct_id": "NCT02842086", "title": "Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pre-Exposure Prophylaxis of HIV-1 Infection" ], "interventions": [ { "name": "F/TAF", "type": "DRUG" }, { "name": "F/TDF", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" }, { "name": "F/TDF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5399, "start_date": "2016-09-02", "completion_date": "2026-07", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-07-24T16:00:05.711Z", "location_count": 54, "location_summary": "Beverly Hills, California • Los Angeles, California • Newport Beach, California + 38 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02842086" }, { "nct_id": "NCT06660173", "title": "A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus (T2DM)" ], "interventions": [ { "name": "Maridebart Cafraglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 409, "start_date": "2024-11-07", "completion_date": "2026-11-10", "has_results": false, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-07-24T16:00:05.711Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Anaheim, California • Canoga Park, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Canoga Park", "state": "California" }, { "city": "Lake Forest", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06660173" }, { "nct_id": "NCT05378529", "title": "A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Atherosclerotic Cardiovascular Disease" ], "interventions": [ { "name": "Lp(a) Screening", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 39480, "start_date": "2022-04-19", "completion_date": "2023-12-30", "has_results": false, "last_update_posted_date": "2025-10-27", "last_synced_at": "2026-07-24T16:00:05.711Z", "location_count": 113, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05378529" }, { "nct_id": "NCT05764161", "title": "A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prurigo Nodularis" ], "interventions": [ { "name": "Ruxolitinib Cream", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 190, "start_date": "2023-06-12", "completion_date": "2025-11-04", "has_results": true, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-07-24T16:00:05.711Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Arkansas City, Arkansas • Los Angeles, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Arkansas City", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Sherman Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05764161" } ] }